Short-term hormone therapy and intermediate dose radiation increases survivial for early stage prostate cancer
Tuesday, November 3, 2009 - 04:42
in Health & Medicine
Short-term hormone therapy given prior to and during intermediate dose radiation treatment for men with early stage prostate cancer increases their chance of living longer, compared to those who receive the same radiation alone, according to a Radiation Therapy Oncology Group (RTOG) study, the largest randomised trial of its kind, presented November 2, 2009, at the American Society for Radiation Oncology (ASTRO) annual meeting. The RTOG trial noted that this benefit appeared to be greatest for men currently defined as at medium-risk for disease failure...
Read the whole article on Science Centric
More from Science Centric
Related
- Short-term hormone therapy and intermediate dose radiation increases survivial for early stage prostate cancerMon, 2 Nov 2009, 12:15:37 EST
- Short-term hormone therapy added to radiation increases survival for medium-risk, but not low-risk, prostate cancer patientsMon, 2 Nov 2009, 11:33:00 EST
- Shorter radiation course stops cancer growth in high-risk prostate cancer patientsTue, 3 Nov 2009, 13:26:31 EST
- Radiation added to hormone therapy increases survival for men with prostate cancerMon, 22 Sep 2008, 8:29:41 EDT
- Shorter radiation course as effective as standard therapy for prostate cancer recurrenceTue, 3 Nov 2009, 13:26:29 EST